应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01530 三生制药
休市中 11-06 16:08:52
15.180
-0.160
-1.04%
最高
15.640
最低
14.800
成交量
1,509万
今开
14.800
昨收
15.340
日振幅
5.48%
总市值
381.63亿
流通市值
381.63亿
总股本
25.14亿
成交额
2.32亿
换手率
0.60%
流通股本
25.14亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
医美概念股局部走高 四环医药（00460）涨2.53% 机构指行业结构性机会持续存在
金吾财讯 · 11-06 10:05
医美概念股局部走高 四环医药（00460）涨2.53% 机构指行业结构性机会持续存在
异动解读｜三生制药盘中上涨5.02%，10月回购633.75万股并持作库存股份
行情直击 · 11-05
异动解读｜三生制药盘中上涨5.02%，10月回购633.75万股并持作库存股份
【券商聚焦】国泰海通证券：美护板块估值及持仓均处底位，看好成长型标的修复弹性
金吾财讯 · 11-05
【券商聚焦】国泰海通证券：美护板块估值及持仓均处底位，看好成长型标的修复弹性
异动解读｜三生制药盘中上涨5.1%，10月回购633.75万股并持作库存股份
行情直击 · 11-04
异动解读｜三生制药盘中上涨5.1%，10月回购633.75万股并持作库存股份
三生制药10月回购633.75万股持作库存股份
财闻 · 11-02
三生制药10月回购633.75万股持作库存股份
三生制药10月股份变动月报表：总股本小幅增加
公告速递 · 11-02
三生制药10月股份变动月报表：总股本小幅增加
【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔
金吾财讯 · 11-02
【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔
【券商聚焦】中信证券：国内医药板块业绩持续修复
金吾财讯 · 11-02
【券商聚焦】中信证券：国内医药板块业绩持续修复
医药股走低 恒生生物科技指数跌2.48% 映恩生物-B（09606）大跌31.05%
金吾财讯 · 10-27
医药股走低 恒生生物科技指数跌2.48% 映恩生物-B（09606）大跌31.05%
异动解读｜三生制药盘中下跌5.03%，近期回购难阻生物科技板块承压
行情直击 · 10-27
异动解读｜三生制药盘中下跌5.03%，近期回购难阻生物科技板块承压
异动解读｜三生制药盘中下跌5.25%，瑞银下调评级至中性
行情直击 · 10-22
异动解读｜三生制药盘中下跌5.25%，瑞银下调评级至中性
三生制药10月14日回购33.75万股股份，涉资约486万港元
公告速递 · 10-14
三生制药10月14日回购33.75万股股份，涉资约486万港元
三生制药(01530)10月13日斥资1165万港元回购80万股
中金财经 · 10-13
三生制药(01530)10月13日斥资1165万港元回购80万股
三生制药10月13日回购80.00万股股份，耗资约1,165.00万港元
公告速递 · 10-13
三生制药10月13日回购80.00万股股份，耗资约1,165.00万港元
三生制药(01530.HK)10月12日斥资1480万港元回购100万股
智通财经 · 10-12
三生制药(01530.HK)10月12日斥资1480万港元回购100万股
三生制药回购100万股股份，耗资约1,480万港元
公告速递 · 10-12
三生制药回购100万股股份，耗资约1,480万港元
汇添富基金管理股份有限公司减持三生制药(01530.HK)499.4万股 每股作价约15.82港元
智通财经 · 10-09
汇添富基金管理股份有限公司减持三生制药(01530.HK)499.4万股 每股作价约15.82港元
三生制药(01530)10月9日斥资3758.8万港元回购250万股
智通财经 · 10-09
三生制药(01530)10月9日斥资3758.8万港元回购250万股
三生制药10月9日回购250万股，耗资约3,758.80万港元
公告速递 · 10-09
三生制药10月9日回购250万股，耗资约3,758.80万港元
三生制药10月8日回购170.00万股，耗资约2,650.00万港元
公告速递 · 10-08
三生制药10月8日回购170.00万股，耗资约2,650.00万港元
加载更多
公司概况
公司名称：
三生制药
所属市场：
SEHK
上市日期：
--
主营业务：
3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":15.18,"timestamp":1793952532003,"preClose":15.34,"halted":0,"volume":15087074,"delay":0,"changeRate":-0.010430247718383322,"floatShares":2514000000,"shares":2514000000,"eps":3.43,"marketStatus":"休市中","change":-0.16,"latestTime":"11-06 16:08:52","open":14.8,"high":15.64,"low":14.8,"amount":231610640,"amplitude":0.054759,"askPrice":15.18,"askSize":4500,"bidPrice":15.17,"bidSize":24000,"shortable":3,"etf":0,"ttmEps":3.750889,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":15.34,"dividendRate":0.016614,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.7526211961155294,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBI.HK","impliedVol":0.5468,"impliedVolPercentile":0.8723},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2681880484","title":"医美概念股局部走高 四环医药（00460）涨2.53% 机构指行业结构性机会持续存在","url":"https://stock-news.laohu8.com/highlight/detail?id=2681880484","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681880484?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:05","pubTimestamp":1793930738,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股局部走高，截至发稿，四环医药（00460）涨2.53%，美丽田园医疗健康（02373）涨1.99%，时代天使（06699）涨2.00%，三生制药（01530）涨1.69%，康哲药业（00867）涨1.61%。消息面上，中信证券研究指，医美行业当前处于上游注册证快速增加的阶段，竞争较为激烈，但结构性机会持续存在：差异化新品红利仍存，营销获客、医学推广、产品组合、渠道运营等综合能力强的上游品牌有望在竞争中胜出。下游显著受益于产业链格局变化，能够夯实自身美誉度、降低获客成本以及提供综合解决方案、提升毛利率的下游品牌有望持续提升份额。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995397","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","BK1100","02373","SG9999015952.SGD","IE00BVYPNQ40.USD","SG9999015978.USD","00867","BK1191","BK1593","BK1215","BK1600","IE00BGHQDM52.EUR","IE00BYV24P56.USD","BK1161","BK1515","01530","00460","SG9999015986.USD","IE00BMCWC346.EUR","SG9999015945.SGD","SG9999004311.SGD","BK1583","06699","IE00BVYPNP33.GBP","HK0000165453.HKD","BK1587","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105495658","title":"异动解读｜三生制药盘中上涨5.02%，10月回购633.75万股并持作库存股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1105495658","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105495658?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:54","pubTimestamp":1793843653,"startTime":"0","endTime":"0","summary":"11月5日，三生制药盘中上涨5.02%，报15.54港元，成交额8021.08万港元。消息面上，公司最新披露截至10月31日的证券变动月报，10月8日至14日期间分五次回购633.75万股，回购价介于14.4港元至15.59港元，均持作库存股份。同期，公司购股权获行使新增66万股，行使价7.62港元，募资502.92万港元；截至10月底，已发行股份为25.14亿股，库存股份为2511.35万股，总股本25.39亿股，并确认符合公众持股量要求。连续回购通常向市场传递公司对估值与长期经营的积极信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"三生制药盘中大涨，连续回购释放积极信号","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090186","title":"【券商聚焦】国泰海通证券：美护板块估值及持仓均处底位，看好成长型标的修复弹性","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090186","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681090186?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:06","pubTimestamp":1793840817,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券研究指，26Q3美护板块收入/归母/扣非同比+10%/-36%/-29%，细分板块中个护稳健，美妆高端好于大众，医美下游好于上游，当前板块估值及持仓均处底位，看好成长型标的修复弹性。该机构推荐：1）基本面强劲的高成长标的；2）估值较低的龙头标的；3）预期低位、后续边际有望改善的标的。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995267","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","BK1215","BK1100","BK1515","02138","BK1161","BK0201","BK1593","LU0502904849.HKD","HK0000165453.HKD","BK1564","BK1191","02373","06699","01530","BK1147","SG9999004311.SGD","161027","01830","BK0012","LU2488822045.USD","BK1585","BK1583","LU0455707207.USD","00460","BK1207","KCE","BK0183","BK0184","BK0188","02367","BK0028","BK1511","01696","02611","BK1600","BK1587","601211","LU2242644610.SGD","02145","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170561826","title":"异动解读｜三生制药盘中上涨5.1%，10月回购633.75万股并持作库存股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1170561826","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170561826?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:59","pubTimestamp":1793771975,"startTime":"0","endTime":"0","summary":"11月4日，三生制药盘中上涨5.1%，报14.64港元，成交额2.48亿港元。消息面上，公司最新披露10月证券变动月报，10月8日至14日期间分五次回购633.75万股，回购价介于14.4港元至15.59港元，均持作库存股份；同期购股权获行使新增66万股，行使价7.62港元，募资502.92万港元。截至10月底，公司已发行股份（不包括库存股份）为25.14亿股，库存股份为2511.35万股，总股本25.39亿股，并确认符合公众持股量要求。连续回购通常向市场传递公司对估值与长期经营的积极信号。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"三生制药盘中上涨，连续回购释放积极信号","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680575445","title":"三生制药10月回购633.75万股持作库存股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680575445","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680575445?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:36","pubTimestamp":1793619360,"startTime":"0","endTime":"0","summary":"11月2日，三生制药(01530.HK)公告，于2026年11月2日向香港联交所提交截至2026年10月31日止月份的证券变动月报表。2026年10月8日至14日期间，公司经2026年6月25日股东大会批准，分五次回购股份并持作库存股份，价格介于每股14.4港元至15.59港元，合计回购633.75万股。同期，公司购股权计划项下期权被行使，涉及新股66万股，行使价为每股7.62港元，所得资金总额为502.92万港元。截至2026年10月底，公司已发行股份(不包括库存股份)为25.14亿股，库存股份为2511.35万股，已发行股份总数为25.39亿股。公司确认已符合适用的公众持股量最低要求。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-11-02/doc-inixiynt0423685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1593","HK0000165453.HKD","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104566898","title":"三生制药10月股份变动月报表：总股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1104566898","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104566898?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:34","pubTimestamp":1793612089,"startTime":"0","endTime":"0","summary":"三生制药于2026年11月2日披露了截至2026年10月31日的股份变动月报表。报告期内，公司法定注册股本保持50,000,000,000股不变，总面值维持在500,000美元。期末公司已发行股份减少至2,513,867,578股，库藏股份增至25,113,500股，总股本上升至2,538,981,078股。公司确认截至本月底，其公众持股量符合香港联交所的相关规定。该月报由公司秘书黎少娟签署。根据公告披露，三生制药已遵守香港联交所《上市规则》和相关法例的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786312","title":"【券商聚焦】中信建投：中国医药资产全球性价比凸显，内外协同空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786312?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:46","pubTimestamp":1793580413,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报称，2026年欧洲内科肿瘤学会 中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。该机构指，中国医药具有“创新升级+供应链韧性”优势，2025年创新药海外授权首付款大幅超去年全年，器械也在积极探索出海路径。美国主导早期研发与高端定价，但跨国药企专利悬崖下需求旺盛，中国资产全球性价比凸显，内外协同空间广阔。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","LU0348767384.USD","LU2476274308.USD","02228","BK1141","06821","KURE","SG9999004311.SGD","LU2399975544.HKD","BK1161","600056","LU1720050803.USD","01789","BK0188","LU1251922891.USD","BK1100","09926","LU0348783233.USD","LU0228659784.USD","BK0028","LU2488822045.USD","03933","LU1969619763.USD","LU0348825331.USD","LU0417516902.SGD","IE00BPRC5H50.USD","BK1515","KCE","09688","LU0634319403.HKD","BK1207","02367","LU0540923850.HKD","LU0348735423.USD","02268","IE00B5MMRT66.SGD","03069","01099","BK1588","LU0307460666.USD","SG9999014674.SGD","BK1617","BK1610","LU2476274720.SGD","LU0348766576.USD","01530","06160","LU0561508036.HKD","LU0588546209.SGD","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","KCE","01276","HK0000320264.USD","BK0028","01093","LU0455707207.USD","LU0588546209.SGD","01952","LU1969619763.USD","LU0348825331.USD","01951","09939","02162","02268","LU0823426480.USD","LU0708995153.HKD","02273","06078","00013","LU0607220059.USD","KURE","LU0708995583.HKD","01530","02269","06821","01548","LU0348766576.USD","09996","LU0039217434.USD","01177","159938","09966","IE00B031HY20.USD","06030","06996","600030","LU0828237510.HKD","LU1064131003.USD","03759","03692","02596","09926","LU1226287529.USD","06990","01801","06160","LU1794554557.SGD","02096","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678140953","title":"医药股走低 恒生生物科技指数跌2.48% 映恩生物-B（09606）大跌31.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678140953","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678140953?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:18","pubTimestamp":1793081937,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股走低，恒生生物科技指数大幅跌2.48%。成分股中，映恩生物-B跌31.05%，亚盛医药跌6.70%，科伦博泰生物跌5.96%，三生制药跌5.10%，石药集团跌4.25%，康方生物跌3.63%，中国生物制药跌3.26%，翰森制药跌3.10%，百济神州跌3.03%。近两个月连锁药房密集推出股权激励，驱动板块逻辑从“政策博弈”转向“业绩锚定”。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994559","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","HK0000500386.USD","LU1961090484.USD","LU1226287792.SGD","LU0634319403.HKD","IE0008369823.USD","06160","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU2476274720.SGD","LU0501845795.SGD","LU2488822045.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","01093","LU0348783233.USD","LU0588546209.SGD","LU1969619763.USD","BK1515","LU0417516902.SGD","09939","LU0348784397.USD","KURE","LU1719994722.HKD","09606","01530","LU2039709279.SGD","LU0348766576.USD","LU1226288253.USD","LU1328277881.USD","BK1583","LU0314109678.HKD","01177","159938","LU0561508036.HKD","LU0880133367.SGD","SG9999004220.SGD","BK1588","IE0008368742.USD","03692","09926","LU0348827113.USD","LU1993786604.SGD","LU1226287529.USD","06855","LU0315179316.USD","06990","BK1593","HK0000252152.HKD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193211941","title":"异动解读｜三生制药盘中下跌5.03%，近期回购难阻生物科技板块承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1193211941","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193211941?lang=zh_cn&edition=full","pubTime":"2026-10-27 10:41","pubTimestamp":1793068888,"startTime":"0","endTime":"0","summary":"10月27日，三生制药盘中下跌5.03%，报13.21港元，成交额1.19亿港元。公开消息面上，公司近期持续实施股份回购。10月9日，公司斥资3758.8万港元回购250万股，回购价为14.98港元至15.18港元；此前10月8日又耗资2650万港元回购170万股。不过，从板块表现看，生物科技股整体偏弱，映恩生物-B跌27.53%，康诺亚-B跌12.41%，科伦博泰生物跌4.75%，康方生物跌3.69%，信达生物跌1.81%。个股回购对短线股价支撑有限。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"三生制药盘中下跌，回购难阻板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174250110","title":"异动解读｜三生制药盘中下跌5.25%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1174250110","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174250110?lang=zh_cn&edition=full","pubTime":"2026-10-22 13:31","pubTimestamp":1792647089,"startTime":"0","endTime":"0","summary":"10月22日，三生制药盘中下跌5.25%，报13.54港元，成交额1.91亿港元。消息面上，瑞银最新将公司评级下调至中性，目标价27元人民币，成为当日股价承压的直接催化。近期公司虽连续实施回购，10月8日至14日累计回购逾633万股，合计动用资金约9540万港元，但回购价格区间约14.40至15.75港元，当前股价已明显低于近期回购均价，显示市场对基本面与估值预期仍偏谨慎。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"三生制药盘中下挫，瑞银下调评级施压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175856521","title":"三生制药10月14日回购33.75万股股份，涉资约486万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175856521","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175856521?lang=zh_cn&edition=full","pubTime":"2026-10-14 17:45","pubTimestamp":1791971151,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月14日发布公告，披露于香港联合交易所场内回购股份事宜。本次回购股份数为337,500股，约占此前公司已发行股本的0.01%。回购价格为每股14.40港元，合计涉资约486万港元。本次回购完成后，截至2026年10月14日，三生制药已发行股本数量变更为2,513,207,578股，库存股份数目相应增至25,113,500股，总已发行股份数维持在2,538,321,078股。据公告显示，三生制药此前于2026年6月25日获得股东大会通过的回购授权，回购股份的剩余额度仍可用于后续股份回购。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药10月14日回购33.75万股股份，涉资约486万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675583353","title":"三生制药(01530)10月13日斥资1165万港元回购80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675583353","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675583353?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:18","pubTimestamp":1791886687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年10月13日，该公司斥资1165万港元回购80万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261013/32395438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01530","BK1583","BK1161","HK0000165453.HKD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118999646","title":"三生制药10月13日回购80.00万股股份，耗资约1,165.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118999646","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118999646?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:56","pubTimestamp":1791885393,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月13日发布翌日报表公告，显示当日公司通过香港联交所场内回购股份80.00万股，占回购前公司已发行股本2,514,345,078股的0.03%。本次回购价格介乎每股14.50港元至14.60港元，合计耗资约1,165.00万港元。回购完成后，公司已发行股本降至2,513,545,078股，库藏股增至24,776,000股，公司已发行股份总数仍为2,538,321,078股。公告显示，三生制药于2026年6月25日获股东大会通过购回股份授权，总数为253,707,141股，其中已回购23,763,000股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药10月13日回购80.00万股股份，耗资约1,165.00万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674592879","title":"三生制药(01530.HK)10月12日斥资1480万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674592879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674592879?lang=zh_cn&edition=full","pubTime":"2026-10-12 18:11","pubTimestamp":1791799891,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1593","01530","HK0000165453.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100162386","title":"三生制药回购100万股股份，耗资约1,480万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100162386","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100162386?lang=zh_cn&edition=full","pubTime":"2026-10-12 18:11","pubTimestamp":1791799879,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月12日公告称，公司于香港联交所场内回购1,000,000股普通股，占该次回购前公司已发行股本约0.04%。此次回购价格介于每股14.70港元至14.90港元之间，总金额约14,800,000港元。公司表示，回购完成后，其已发行股本变动为2,514,345,078股，库藏股数量增至23,976,000股，股本总数为2,538,321,078股。根据公告，三生制药此前于2026年6月25日已通过回购授权，总额度为253,707,141股；迄今为止，公司已根据该授权累计回购22,963,000股，占授权通过当日已发行股本的约0.91%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药回购100万股股份，耗资约1,480万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856463","title":"汇添富基金管理股份有限公司减持三生制药(01530.HK)499.4万股 每股作价约15.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674856463?lang=zh_cn&edition=full","pubTime":"2026-10-09 19:10","pubTimestamp":1791544217,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01530","BK1583","BK1593","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674559278","title":"三生制药(01530)10月9日斥资3758.8万港元回购250万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674559278","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674559278?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:41","pubTimestamp":1791542518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，该公司于2026年10月9日斥资3758.8万港元回购250万股股份，每股回购价格为14.98-15.18港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1593","BK1161","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114709376","title":"三生制药10月9日回购250万股，耗资约3,758.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114709376","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114709376?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:41","pubTimestamp":1791542516,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月9日公告称，公司在香港联合交易所场内回购普通股250万股，占该次回购前公司已发行股本约0.1%。本次回购每股价格介乎14.98港元至15.18港元，合计耗资约3,758.80万港元。回购完成后，公司已发行股份总数减少至2,515,345,078股，库藏股数量相应增至22,976,000股。公告显示，本次股份回购基于公司于2026年6月25日通过的购回授权。相关授权允许公司最多回购253,707,141股，迄今公司已回购21,963,000股，占授权总数约0.87%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药10月9日回购250万股，耗资约3,758.80万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156842934","title":"三生制药10月8日回购170.00万股，耗资约2,650.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156842934","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156842934?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:26","pubTimestamp":1791455176,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月8日发布公告，当日通过香港联交所场内回购普通股170.00万股，约占公司回购前已发行股本的0.07%。回购价格区间为每股15.40港元至15.75港元，合计耗资26,500,000港元。本次回购完成后，公司已发行股份总数减至2,517,845,078股，库藏股数增加至20,476,000股。截至公告日，公司可根据2026年6月25日通过的购回授权继续回购最多253,707,141股股份。公司明确表示，已遵守香港联合交易所有限公司证券上市规则及相关法例的规定。本次公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药10月8日回购170.00万股，耗资约2,650.00万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":0.1211},{"period":"1month","weight":-0.0331},{"period":"3month","weight":-0.1553},{"period":"6month","weight":-0.3098},{"period":"1year","weight":-0.4995},{"period":"ytd","weight":-0.3629}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006634},{"month":2,"riseRate":0.454545,"avgChangeRate":0.001777},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113184},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080953},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025359},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.034677},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.015863},{"month":9,"riseRate":0.666667,"avgChangeRate":0.027514},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.03203},{"month":11,"riseRate":0.75,"avgChangeRate":0.065028},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045348}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}